

What is claimed is:

SUB A' 1. An antisense compound 8 to 30 nucleotides in length targeted to a nucleic acid molecule encoding TNFR1, wherein said antisense compound inhibits the expression of TNFR1.

5

SUB B' 2. The antisense compound of claim 1 which is an antisense oligonucleotide.

3. The oligonucleotide of claim 2 comprising at least
10 an 8-nucleobase portion of SEQ ID NO 11, 15, 16, 17, 21, 22,
23, 25, 28, 29, 30, 31, 33, 35, 36, 37, 38, 39, 41, 42, 43, 45,
46, 47, 48, 50, 59, 62, 67, 70, 71, 74, 76, 77, 78, 81, 82, 84,
90, 91, 94, 95, 96, 98, 99, 100, 101, 102, 103, 104, 108, 111,
112, 113, 117, 118, 127, 131, 132, 133, 134, 136, 140, 143,
15 144, 158, 159, 168, 170, 171, 173, 174, 175, 176, 177, 178,
179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190,
191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202,
203, 204, 206, 207, 208, 209, 211, 212, 213, 214, 215, 217,
218, 220, 221, 222, 224, 225, 226, 227, 229, 230, 231, 232,
20 233, 234, 235, 236, 237, 238, 239, 240, 242, 243, 244 or 246.

4. The oligonucleotide of claim 2 comprising SEQ ID NO:
11, 15, 16, 17, 22, 30, 33, 70, 74, 76 and 78.

5. The oligonucleotide of claim 2 which comprises at
least one modified internucleoside linkage.

25

SUB B' 6. The oligonucleotide of claim 5 wherein the modified
internucleoside linkage is a phosphorothioate linkage.

7. The oligonucleotide of claim 2 which comprises at
least one modified sugar moiety.

09695451.102400

8. The oligonucleotide of claim 7 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

9. The oligonucleotide of claim 2 which comprises at least one modified nucleobase.

5 10. The oligonucleotide of claim 9 wherein the modified nucleobase is a 5-methylcytosine.

11. The oligonucleotide of claim 2 which is a chimeric oligonucleotide.

12. A pharmaceutical composition comprising the
10 antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

13. The pharmaceutical composition of claim 12
comprising a colloidal dispersion system.

14. The pharmaceutical composition of claim 12 wherein
15 the antisense compound is an antisense oligonucleotide.

15. A method of inhibiting the expression of TNFR1 in cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so that expression of TNFR1 is inhibited.

20 16. The method of claim 15 wherein said cells or tissues are human cells or tissues or murine cells or tissues.

17. A method of treating an animal having a disease or condition associated with TNFR1 comprising administering to said animal a therapeutically or prophylactically effective
25 amount of the antisense compound of claim 1 so that expression of TNFR1 is inhibited.

004201754560

SUB
B'

18. The method of claim 17 wherein said animal is a human.

19. The method of claim 17 wherein the disease or
5 condition is a liver disease.

20. The method of claim 19 wherein the liver disease is hepatitis.

21. The method of claim 17 wherein the disease or
10 condition is liver injury.

22. The method of of claim 17 wherein the disease or condition is a hyperproliferative disorder.

23. The method of claim 22 wherein the hyperproliferative disorder is cancer.

15 24. The method of of claim 23 wherein the cancer is liver cancer.

549
B1

09695451.102400